Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,781 total articles

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Phathom Pharmaceuticals announced it will report its Q1 2026 financial results and provide a business update via a live webcast on April 30, 2026. The company focuses on developing and commercializing novel gastrointestinal disease treatments, including its marketed product VOQUEZNA for GERD and H. pylori infection treatment in the U.S.

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

LENZ Therapeutics has submitted a Marketing Authorization Application to the UK's MHRA for VIZZ®, an FDA-approved aceclidine-based eye drop for presbyopia treatment. This marks the sixth regulatory submission outside the US as LENZ advances international commercialization efforts following positive Phase 3 trial results and early US market launch.

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Air's subsidiary, Beyond Cancer, presented updated Phase 1 clinical data for its investigational immunotherapy UNO at AACR 2026, reporting prolonged survival in heavily pretreated cancer patients after a single intratumoral injection. The trial included patients with breast cancer, squamous cell carcinoma, and melanoma, many of whom had exha…

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics presented new scientific data and advancements at the AACR 2026 Annual Meeting, emphasizing the potential of their allogeneic CAR T cell therapies to provide off-the-shelf, scalable, and accessible treatment options for cancer and autoimmune diseases. The company showcased dual-targeting technology and expanded their pipeline,…

Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition

Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition

Super League Enterprise, Inc. announced a shareholder letter encouraging support for its acquisition of the Misfits Ads Division. The acquisition is expected to add profitable revenue, improve financial predictability, expand market share, and speed the company's path to sustainable cash-based EBITDA profitability. The transaction diversifies reven…

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Immuneering Corporation presented new genetic data at the AACR Annual Meeting demonstrating that their MEK inhibitor, atebimetinib, rarely induces common resistance mutations in the MAPK pathway in treated patients. This supports the drug's potential for durable tumor shrinkage and improved survival in first-line pancreatic cancer. The company is a…

KBRA Affirms Ratings for Preferred Bank

KBRA Affirms Ratings for Preferred Bank

Kroll Bond Rating Agency (KBRA) has affirmed Preferred Bank's deposit and debt ratings with a stable outlook, highlighting the bank's robust profitability, high-yield loan portfolio, and efficient branch-light business model. The strong 2025 return on assets (ROA) of 1.84% underpins these ratings. Preferred Bank continues to serve a diverse custome…

Radware Announces 2026 Annual General Meeting

Radware Announces 2026 Annual General Meeting

Radware Ltd. announces its 2026 Annual General Meeting (AGM) to be held on May 25, 2026, at its New Jersey office. The agenda includes electing Class III directors, approving equity awards and bonus structure for the CEO, and reappointing the audit firm Kost Forer Gabbay & Kasierer. Financial statements for 2025 will also be presented and discussed…

Parsons Demand Response Technology to Optimize and Enable Los Angeles Department of Water & Power’s Operations and Strategic Plan

Parsons Demand Response Technology to Optimize and Enable Los Angeles Department of Water & Power’s Operations and Strategic Plan

Parsons Corporation has been selected by the Los Angeles Department of Water & Power (LADWP) to implement its Demand Response Management System (DRMS), significantly boosting LADWP's capacity to integrate distributed energy resources as part of its strategic plan to achieve 100% clean electricity by 2035 or sooner. This contract will enhance grid r…

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

Ascentage Pharma presented four preclinical studies at AACR 2026 demonstrating the efficacy and synergistic potential of its drug candidates Olverembatinib, APG-2449, and APG-5918 in treating various cancers. These findings support further clinical development and combination therapy strategies for hematologic malignancies and solid tumors, highlig…

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

ANI Pharmaceuticals announces FDA approval and commercial launch of Pimozide Tablets (1 mg and 2 mg), a generic version of Orap®, with 180-day exclusivity for first generic competition. The product targets a market with approximate annual U.S. sales of $3.1 million, supporting ANI's strategy to deliver limited competition generic products and expan…

Fiserv to Present at Upcoming Investor Conferences

Fiserv to Present at Upcoming Investor Conferences

Fiserv, Inc., a leading global provider of payments and financial services technology, announced its CEO Mike Lyons will present at major upcoming investor conferences in May, including the J.P. Morgan Global Technology, Media, and Communications Conference and the Bernstein Strategic Decisions Conference. The presentations will be webcast and avai…

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio announced updated interim data from its Phase 1/2 upliFT-D trial of PBFT02 for frontotemporal dementia with GRN mutations, showing reductions in brain atrophy and stabilization of plasma neurofilament levels in early-stage patients. Despite encouraging biomarker improvements and safety profile, the FDA requires a randomized controlled t…

Capital City Bank Group, Inc. Reports First Quarter 2026 Results

Capital City Bank Group, Inc. Reports First Quarter 2026 Results

Capital City Bank Group, Inc. reported first quarter 2026 net income of $15.8 million, $0.92 per diluted share, showing a 15% increase over the prior quarter despite slightly lower net interest income due to fewer calendar days. The bank achieved improved returns on assets and equity, stable credit quality, and strong deposit growth. Noninterest ex…